Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Novo Nordisk A/S ADR (NVO)

Novo Nordisk A/S ADR (NVO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 193,470,384
  • Shares Outstanding, K 2,354,800
  • Annual Sales, $ 19,448 M
  • Annual Income, $ 6,456 M
  • 60-Month Beta 0.42
  • Price/Sales 10.01
  • Price/Cash Flow 26.53
  • Price/Book 20.43
Trade NVO with:

Options Overview

Details
  • Implied Volatility 18.57%
  • Historical Volatility 14.84%
  • IV Percentile 2%
  • IV Rank 3.25%
  • IV High 35.38% on 10/28/20
  • IV Low 18.00% on 05/07/21
  • Put/Call Vol Ratio 0.62
  • Today's Volume 295
  • Volume Avg (30-Day) 1,385
  • Put/Call OI Ratio 0.26
  • Today's Open Interest 22,885
  • Open Int (30-Day) 26,683

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/21
See More
  • Average Estimate 0.81
  • Number of Estimates 2
  • High Estimate 0.82
  • Low Estimate 0.79
  • Prior Year 0.67
  • Growth Rate Est. (year over year) +20.90%

Price Performance

See More
Period Period Low Period High Performance
1-Month
78.71 +3.74%
on 06/03/21
84.94 -3.87%
on 06/10/21
+0.35 (+0.43%)
since 05/21/21
3-Month
66.59 +22.62%
on 03/26/21
84.94 -3.87%
on 06/10/21
+13.66 (+20.09%)
since 03/23/21
52-Week
63.22 +29.15%
on 10/30/20
84.94 -3.87%
on 06/10/21
+13.71 (+20.18%)
since 06/23/20

Most Recent Stories

More News
Disposable Insulin Pen Market Improvement, Formulation, And CAGR 2031 | BD and Levemir

Market.us research covers the present framework on and examinations of the business potential for each geological district in light of worldwide market size, at regional and country-level market size,...

NVO : 81.65 (-0.62%)
AMRA Medical Collaborates on Clinical Trial Assessing the Impact of Liraglutide on Body Fat Distribution

LINK�PING, , /PRNewswire/ -- Researchers from the University Hospitals Cleveland Medical Center and the Southwestern (UTSW) Medical Center conducted a phase 4, randomized clinical trial ().This independent...

NVO : 81.65 (-0.62%)
Drugs For Hormonal Replacement Therapy Global Market Report 2021: COVID-19 Impact And Recovery To 2030

Reportlinker.com announces the release of the report "Drugs For Hormonal Replacement Therapy Global Market Report 2021: COVID-19 Impact And Recovery To 2030" - https://www.reportlinker.com/p06097025/?utm_source=GNW...

BAYRY : 15.1900 (-1.17%)
LLY : 217.10 (-1.96%)
NVO : 81.65 (-0.62%)
PFE : 39.05 (-1.41%)
Ocugen, Inc. Announces Ken Inchausti as Head, Investor Relations & Communications

Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19,...

NVO : 81.65 (-0.62%)
OCGN : 7.56 (+2.02%)
Amalgam Rx(TM) and Novo Nordisk(R) Plan Global Expansion

Amalgam Rx, Inc., the leader in connecting healthcare providers and life sciences companies through a SaaS-enabled digital marketplace and product platform, is announcing global expansion of its insulin...

NVO : 81.65 (-0.62%)
Novo Nordisk to present research across diabetes and obesity portfolio at the 81st Annual American Diabetes Association Scientific Sessions

/PRNewswire/ -- Novo Nordisk announced that new data from more than 30 abstracts will be presented from the company's approved and investigational medicines highlighting its broad diabetes and obesity...

NVO : 81.65 (-0.62%)
Lumen Bioscience and Novo Nordisk Enter into Research Collaboration to Explore Novel Strategies to Deliver Oral Biologics for Cardiometabolic Disease

/PRNewswire/ -- , a clinical-stage biopharmaceutical company developing biologic drugs for highly prevalent diseases, announced today it has entered into a research collaboration with Novo Nordisk to evaluate...

NVO : 81.65 (-0.62%)
Ascendis' (ASND) BLA for GHD Candidate Gets Review Extension

Ascendis (ASND) is seeking approval for lonapegsomatropin as a potential treatment of pediatric growth hormone deficiency.

PFE : 39.05 (-1.41%)
NVO : 81.65 (-0.62%)
ASND : 138.77 (-0.87%)
IMAB : 78.99 (-0.14%)
The Zacks Analyst Blog Highlights: Microsoft, Nike, Novo Nordisk, Caterpillar and General Electric

The Zacks Analyst Blog Highlights: Microsoft, Nike, Novo Nordisk, Caterpillar and General Electric

GE : 12.95 (-0.61%)
MSFT : 265.27 (-0.09%)
CAT : 213.79 (+0.31%)
NKE : 133.10 (+0.47%)
NVO : 81.65 (-0.62%)
Gilead (GILD) Gets FDA Nod for Label Expansion of Epclusa

Gilead (GILD) obtains FDA approval for the label expansion of HCV drug, Epclusa, to include children as well.

GSK : 39.85 (+1.97%)
NVO : 81.65 (-0.62%)
GILD : 66.65 (-0.60%)
RGEN : 192.92 (-2.15%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Novo Nordisk is a world leader in insulin and diabetes care and also manufactures and markets a variety of other pharmaceutical products. Furthermore the company is the world's largest producer of industrial enzyme products. The company believes that everyone must care for the environment and our natural...

See More

Key Turning Points

3rd Resistance Point 83.18
2nd Resistance Point 82.88
1st Resistance Point 82.26
Last Price 81.65
1st Support Level 81.34
2nd Support Level 81.04
3rd Support Level 80.42

See More

52-Week High 84.94
Last Price 81.65
Fibonacci 61.8% 76.64
Fibonacci 50% 74.08
Fibonacci 38.2% 71.52
52-Week Low 63.22

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar